<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04288765</url>
  </required_header>
  <id_info>
    <org_study_id>HAL 319/2019</org_study_id>
    <nct_id>NCT04288765</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma</brief_title>
  <official_title>Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Cooperativo de Hemopatías Malignas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Cooperativo de Hemopatías Malignas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce
      profound clinical responses. The investigators want to observe the effectiveness of the
      quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients
      receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8
      cycles of KRDd without autologous stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with newly diagnosed and previously untreated multiple myeloma living in Mexico that are fit for a quadruple therapy for multiple myeloma. Those patients that aren't fit or unavailable for transplant will go to the continuous treatment arm. The stratification of the study will be done by age and by cytogenetic risk.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response with negative minimal residual disease</measure>
    <time_frame>10 months</time_frame>
    <description>Complete response with MRD-negative disease measured by inmunophenotype with the International Myeloma Working Group response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival measured on months on both study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>36 months</time_frame>
    <description>Progression free survival measured on months from the time to the end of treatment to disease progression on both study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Rate of adverse events rated grade ≥3 by CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Group A - Non transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib Lenalidomide Daratumumab Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carfilzomib Lenalidomide Daratumumab Dexamethasone Autologous stem cell transplantation (ASCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab Only Product in Parenteral Dose Form</intervention_name>
    <description>Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21
Daratumumab:
Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly</description>
    <arm_group_label>Group A - Non transplant</arm_group_label>
    <arm_group_label>Group B - transplant</arm_group_label>
    <other_name>Lenalidomide</other_name>
    <other_name>Carfilzomib</other_name>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly diagnosed and previously untreated multiple myeloma by the
             International Myeloma Working Group criteria that requires treatment based on:
             Presence of elevated calcium, renal failure, anemia and/or bone lesions (CRAB) Clonal
             bone marrow plasma cells ³ 60% Involved/uninvolved serum free light chain ratio ³ 100
             &gt;1 focal lesions on MRI studies (³5 mm in size)

          2. Age &gt; 18 years

          3. Functional stage of 0 - 1 measured by the Eastern Cooperative Oncology Group (ECOG)
             scale.

          4. Capacity and willingness to provide a written informed consent.

        Exclusion Criteria:

          1. POEMS syndrome

          2. Systemic amyloidosis

          3. Plasma cells leukemia

          4. Radiotherapy on multiple sites on the period of 4 weeks before the initiation of
             treatment (1 week if it is one region)

          5. Improper liver function: total bilirubin &gt; 1.5 x upper limit of normal (ULN) or &gt; 3 x
             ULN in patients with Gilbert syndrome, alanine aminotransferase (ALT) and aspartate
             aminotransferase (AST) &gt; 3.0 x ULN.

          6. Non-controlled systematic active infection (viral, bacterial and/or fungic).

          7. Patients with known infection by human immunodeficiency virus (HIV).

          8. Active infection by hepatitis B.

          9. Active infection by hepatitis C.

         10. Significant cardiovascular diseases as uncontrolled or symptomatic arrhythmias,
             congestive heart failure or acute myocardial infarction within 2 months prior to
             screening, or any New York Heart Association (NYHA) class 3 or 4 heart disease.

         11. Diagnosis of previous malignancies for 2 years, with exception of patients with basal
             or squamous cell carcinoma or &quot;in situ&quot; carcinoma of cervix or breast.

         12. History of allergic reaction or severe anaphylaxis to humanized or murine monoclonal
             antibodies.

         13. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grupo Cooperativo de Hemopatías Malignas</name>
      <address>
        <city>Huixquilucan</city>
        <state>Estado De México</state>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Ovilla-Martinez, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>ovillarob@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela E Baez Islas, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>drabaez.hematologia@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly diagnosed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

